Pfizer Global Research and Development, 500 Arcola Road, Collegeville, PA 19426, USA.
Bioorg Med Chem Lett. 2010 Mar 1;20(5):1555-8. doi: 10.1016/j.bmcl.2010.01.056. Epub 2010 Jan 20.
Two related series of selective norepinephrine reuptake inhibitors were synthesized based on 3,4-dihydro-1H-2,1,3-benzothiadiazine 2,2-dioxide or 3,4-dihydrosulfostyril cores, and screened for monoamine reuptake inhibition. Structure-activity relationships were determined for the series' in vitro potency and selectivity versus serotonin or dopamine transporter inhibition, and analogs based on both cores were identified as potent and selective NRIs. The 3,4-dihydrosulfostyril series was further tested for microsome stability, and compound 16j, which was optimized for both potency and stability, showed efficacy in an in vivo model of thermoregulatory dysfunction.
基于 3,4-二氢-1H-2,1,3-苯并噻二嗪 2,2-二氧化物或 3,4-二氢亚磺酰基噻唑核,合成了两个相关的选择性去甲肾上腺素再摄取抑制剂系列,并对其进行了单胺再摄取抑制作用的筛选。对该系列化合物的体外活性和对 5-羟色胺或多巴胺转运体抑制的选择性进行了构效关系研究,发现基于这两个核的类似物具有很强的选择性和抑制作用。进一步对 3,4-二氢亚磺酰基噻唑系列化合物进行了微粒体稳定性测试,优化了化合物 16j 的活性和稳定性,在体温调节功能障碍的体内模型中显示出疗效。